STX-1200
/ Scribe Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 05, 2026
A Single Administration of STX-1200 CRISPR-CasX Gene Editor Achieves Robust and Durable Reduction of Lipoprotein(a) Across Preclinical Models
(AHA 2026)
- No abstract available
Preclinical • Cardiovascular
1 to 1
Of
1
Go to page
1